CDISC Therapeutic Area Data Standards: User Guide for Breast Cancer (Version 1.0) © 2016 Clinical Data Interchange Standards Consortium, Inc. All rights reserved Page 67 Provisional May 16, 2016 27. National Cancer Institute. Se ntinel Lymph Node Biopsy. National Cancer Institute. http://www.cancer.gov/about -cancer/diagnosis -staging/staging/sentinel -node -biopsy -fact-sheet. Published August 11, 2011. Accessed February 23, 2015. 28. Anderson BO, Calhoun KE, Rosen EL. Evolving concepts in the management of lobular neoplasia. J Natl Compr Canc Netw . 2006;4(5):511- 522. 29. Cohen MA. Cancer upgrades at excisional biopsy after diagnosis of atypical lobular hyperplasia or lobular carcinoma in situ at core -needle biopsy: some reasons why. Radiology . 2004;231(3):617- 621. doi:10.1148/radiol.2313040154. 30. Goss PE, Ingle JN, Pritchard KI, et al. Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27 --a randomized controlled phase III trial. J Clin Oncol . 2013;31(11):1398 - 1404. doi:10.1200/JCO.2012.44.7805. 31. Breast Cancer. Merck Manuals Professional Edition. http://www.merckmanuals.com/professional/gynecology -and-obstetrics/breast -disorders/breast -cancer. Published October 2013. Accessed February 24, 2015. 32. Petit T, Borel C, Ghnassia JP, et al. Chemotherapy response of breast cancer depends on HER -2 status and anthracycline dose intensity in the neoadjuvant setting. Clin Cancer Res . 2001;7(6):1577- 1581. Further Reading The following works are of interest to this document, but were not actively cited within it: • Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer . 2009;45(2):228 -47. doi: 10.1016/j.ejca.2008.10.026. • GEN. 15 Breast Cancer Drugs in the Pipeline Right Now. GEN | Genetic Engineering & Biotechnology Ne ws - Biotech from Bench to Business . Nov 27, 2012. Available at: http://www.genengnews.com/insight -and- intelligenceand153/15 -breast -cancer -drugs -in-the-pipeline -right- now/77899728/ . Accessed January 20, 2015. • National Cancer Institute. Targeted Cancer Therapies Fact Sheet. Comprehensive Cancer Information - National Cancer Institute . April 25, 2014. Available at: http://www.cancer.gov/cancertopics/factsheet/Therapy/targeted . Accessed January 20, 2015. • Niederhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE. Cancer of the Breast. Abeloff’s Clinic al Oncology . 5th ed. New York: Churchill Livingstone; 2014. • U.S. Department of Health and Human Services, Food and Drug Administration, CDER. Guidance for Industry: Pathological Complete Response in Neoadjuvant Treatment of High -Risk Early -Stage Breast Cancer: Use as an Endpoint to Support Accelerated Approval . Silver Spring, MD: Food and Drug Administration; 2014. • Wolchok JD, Hoos A, O’Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune -related response criteria. Clin Cancer Res . 2009;15:7412.